Ceruloplasmin Is a Potential Biomarker for aGvHD following Allogeneic Hematopoietic Stem Cell Transplantation

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Lv, Meng ^a   Ye, Hai Ge ^a,b   Zhao, Xiao Su ^a   Zhao, Xiang Yu ^a   Chang, Ying Jun ^a   Liu, Dai Hong ^a   Xu, Lan Ping ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CERULOPLASMIN; COMPLEMENT FACTOR H; CORTICOSTEROID; MYELOPEROXIDASE; OROSOMUCOID;

8 PLEX ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTITATION; ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BIOPSY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT INFECTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; QUANTITATIVE ASSAY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CERULOPLASMIN; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KINETICS; MALE; MIDDLE AGED; PROGNOSIS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; ROC CURVE; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84874727720     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058735     Document Type: Article

References (28)

1. Ferrara JL, Levine JE, Reddy P, Holler E, (2009) Graft-versus-host disease. Lancet 373: 1550-1561.
2. Huang XJ, Wan J, Lu DP, (2001) Serum TNFalpha levels in patients with acute graft-versus-host disease after bone marrow transplantation. Leukemia 15: 1089-1091.
3. Choi SW, Kitko CL, Braun T, Paczesny S, Yanik G, et al. (2008) Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 112: 1539-1542.
4. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, et al. (2009) A biomarker panel for acute graft-versus-host disease. Blood 113: 273-278.
5. Ferrara JL, Harris AC, Greenson JK, Braun TM, Holler E, et al. (2011) Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 118: 6702-6708.
6. Levine JE, Logan BR, Wu J, Alousi AM, Bolanos-Meade J, et al. (2012) Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. Blood 119: 3854-3860.
7. Ye H, Sun L, Huang X, Zhang P, Zhao X, (2010) A proteomic approach for plasma biomarker discovery with 8-plex iTRAQ labeling and SCX-LC-MS/MS. Mol Cell Biochem 343: 91-99.
8. Ye H, Lv M, Zhao X, Huang X, (2012) Plasma level of lipopolysaccharide-binding protein is indicative of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Int J Hematol 95: 680-688.
9. Weiss KH, Stremmel W, (2012) Evolving perspectives in Wilson disease: diagnosis, treatment and monitoring. Curr Gastroenterol Rep 14: 1-7.
10. Giurgea N, Constantinescu MI, Stanciu R, Suciu S, Muresan A, (2005) Ceruloplasmin- acute-phase reactant or endogenous antioxidant? The case of cardiovascular disease. Med Sci Monit 11: RA48-51.
11. Healy J, Tipton K, (2007) Ceruloplasmin and what it might do. J Neural Transm 114: 777-781.
12. Huang XJ, Zhu HH, Chang YJ, Xu LP, Liu DH, et al. (2012) The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission. Blood 119: 5584-5590.
13. Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Yu W, et al. (2009) Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 15: 4777-4783.
14. Chang YJ, Huang XJ, (2012) Haploidentical hematopoietic stem cell transplantation with unmanipulated granulocyte colony stimulating factor mobilized marrow and blood grafts. Curr Opin Hematol 19: 454-461.
15. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, et al. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15: 825-828.
16. Martin PJ, (2008) Study design and endpoints in graft-versus-host disease. Best Pract Res Clin Haematol 21: 357-372.
17. +MacMillan ML, DeFor TE, Weisdorf DJ, (2010) The best endpoint for acute GVHD treatment trials. Blood 115: 5412-5417.
18. Li TW, Zheng BR, Huang ZX, Lin Q, Zhao LK, et al. (2010) Screening disease-associated proteins from sera of patients with rheumatoid arthritis: a comparative proteomic study. Chin Med J (Engl) 123: 537-543.
19. Hrycek A, Pochopien-Kenig G, Scieszka J, (2007) Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide. Autoimmunity 40: 217-222.
20. Amer J, Weiss L, Reich S, Shapira MY, Slavin S, et al. (2007) The oxidative status of blood cells in a murine model of graft-versus-host disease. Ann Hematol 86: 753-758.
21. Sidhu A, Miller PJ, Hollenbach AD, (2011) FOXO1 stimulates ceruloplasmin promoter activity in human hepatoma cells treated with IL-6. Biochem Biophys Res Commun 404: 963-967.
22. Paradis M, Gagne J, Mateescu MA, Paquin J, (2010) The effects of nitric oxide-oxidase and putative glutathione-peroxidase activities of ceruloplasmin on the viability of cardiomyocytes exposed to hydrogen peroxide. Free Radic Biol Med 49: 2019-2027.
23. Shiva S, Wang X, Ringwood LA, Xu X, Yuditskaya S, et al. (2006) Ceruloplasmin is a NO oxidase and nitrite synthase that determines endocrine NO homeostasis. Nat Chem Biol 2: 486-493.
24. Koc M, Taysi S, Sezen O, Bakan N, (2003) Levels of some acute-phase proteins in the serum of patients with cancer during radiotherapy. Biol Pharm Bull 26: 1494-1497.
25. Chen YB, Cutler CS (2012) Biomarkers for acute GVHD: can we predict the unpredictable? Bone Marrow Transplant.
26. Chiarla C, Giovannini I, Siegel JH, (2008) Patterns of correlation of plasma ceruloplasmin in sepsis. J Surg Res 144: 107-110.
27. Natesha RK, Natesha R, Victory D, Barnwell SP, Hoover EL, (1992) A prognostic role for ceruloplasmin in the diagnosis of indolent and recurrent inflammation. J Natl Med Assoc 84: 781-784.
28. Paczesny S, Braun TM, Levine JE, Hogan J, Crawford J, et al. (2010) Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2: 13ra12.